<DOC>
	<DOCNO>NCT01982071</DOCNO>
	<brief_summary>To evaluate efficacy safety intravenous micafungin treatment patient proven probable fungal infection cause Candida sp . ( Fungemia , respiratory mycosis , gastrointestinal mycosis ) adult patient China .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Micafungin Against Invasive Candidiasis Candidemia</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>The diagnosis criterion probable candida infection : Risk factor + Clinical Manifestations + positive finding include microbiologic test The diagnosis criterion proven candida infection : Risk factor + Clinical Manifestation + positive finding include microbiologic test + tissue culture pathological examination result The follow 3 criterion must meet patient diagnose probable candida pneumonia : 1 . Risk factor ( ) infection 2 . Clinical manifestation infection pulmonary infection explain pathogenic infection 3 . Two positive sputum culture Candida Patient receive antifungal drug within 1 month prior enrollment . HIV positive patient Patients organ transplant Patients agranulocytosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>candidiasis</keyword>
	<keyword>candidemia</keyword>
	<keyword>Open-label design</keyword>
</DOC>